Global Generic Trends

A generic drug (generic drugs, short: generics) is a drug defined as "a drug product that is comparable to a brand/reference listed drug product in dosage form, strength, quality and performance characteristics, and intended use. It has also been defined as a term referring to any drug marketed under its chemical name without advertising or to the chemical makeup of a drug rather than to the advertised brand name under which the drug is sold. Although they may not be associated with a particular company, generic drugs are subject to the regulations of the governments of countries where they are dispensed. Global generic are labelled with the name of the manufacturer and the adopted name (non-proprietary name) of the drug. A generic drug must contain the same active ingredients as the original formulation

The global generic drug market should grow at a compound annual growth rate of 15% over five years to be worth just under $169 billion in 2014, according to a report from BCC Research. The "Generic Drugs Market: 2015 - 2030 - Opportunities, Challenges, Strategies & Forecasts" report presents an in-depth assessment of the generic drugs ecosystem including technology, economics, key trends, market drivers, challenges, investment potential, regulatory landscape, leading therapies, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents market size forecasts for generic drugs from 2015 through to 2030. The forecasts are segmented for over 10 therapeutic areas, 3 brand classifications, 5 regions and 25 leading countries

The proliferation of generic drugs  largely has been hailed as an economic and consumer triumph.  In 2013, more than 85% of all prescriptions in the United States were filled by generic drugs.  Under FDA regulations, generic drugs must be chemically equivalent, have the same active ingredients, and be bioequivalent to their branded counterparts.  However, the requirements for safety labelling on branded and generic drugs differ in important ways. Most notably, while a branded drug manufacturer is responsible for the accuracy and adequacy of its drug label, a generic drug company is responsible for ensuring that its warning label is the same as the label of the brand-name reference listed drug (RLD).

  • Anti-counterfeiting trade agreement criminalizing generic medicine (ACTA)
  • Pharmacokinetic and pharmacodynamics properties of generic drugs
  • Protectionism
  • Implementation of TRIPS in developing countries
  • Safety mechanisms for generic medicines
  • Generic drug labelling
  • Market Access Pricing and Reimbursement
  • Major market trends
  • Featured regional market trends

Related Conference of Global Generic Trends

September 25-26, 2017(10 Plenary Forums- 1 Event)

7th International Conference and Exhibition on Pharmaceutical Regulatory Affairs and IPR

Chicago, Illinois, USA
September 25-26, 2017
(10 Plenary Forums - 1Event)

6th International Conference and Exhibition on GMP, GCP & Quality Control

Chicago, Illinois, USA
October 16-18, 2017

12th World Pharma Congress

Budapest, Hungary
October 16-18, 2017

11th World Drug Delivery Summit

(10 Plenary Forums - 1Event)
Baltimore, Maryland, USA
October 16-17, 2017

10th International Conference and Exhibition on Biologics and Biosimilars

San Francisco, California, USA
November 09-11, 2017

4th European Biopharma Congress

Vienna, Austria
August 20-22, 2018

9th Asian Biologics and Biosimilars Congress

Tokyo, Japan

Global Generic Trends Conference Speakers

Recommended Sessions

Related Journals

Are you interested in